1. Bouzourene H, Chaubert P, Seelentag W, Bosman FT, and Saraga E (1999). Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease. Hum Pathol 30: 66–71.
2. Bova GS, Fox WM, and Epstein JI (1993). Methods of radical prostatectomy specimen processing: A novel technique for harvesting fresh prostate cancer tissue and review of processing techniques. Mod Pathol 6: 201–207.
3. Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P, Rhim JS, Linehan WM, and Topalian SL (1997). Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res 57: 995–1002.
4. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, and Strober W (1992). Quantitation of apoptotic index and cell viability using fluorescent dyes. In: Coligan JE, editor. Current protocols in immunology, vol 1. New York: Wiley Interscience, 3.17.
5. Dunipace AJ, Beaven R, Noblitt T, Li Y, Zunt S, and Stookey G (1992). Mutagenic potential of toluidine blue evaluated in the Ames test. Mutat Res 279: 255–259.